NCT00858117View on ClinicalTrials.gov

A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 26, 2005

Primary Completion Date

March 17, 2010

Study Completion Date

January 24, 2013

Conditions
Leukemia
Interventions
BIOLOGICAL

Alemtuzumab

Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks

BIOLOGICAL

Rituximab

Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks

Trial Locations (1)

60611

Northwestern University, Northwestern Medical Faculty Foundation, Chicago

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Northwestern University

OTHER